Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.

Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ.

J Clin Oncol. 2009 Jun 1;27(16):2604-14. doi: 10.1200/JCO.2008.20.6300. Epub 2009 Apr 6.

2.

Irinogenetics: how many stars are there in the sky?

Mathijssen RH, Gurney H.

J Clin Oncol. 2009 Jun 1;27(16):2578-9. doi: 10.1200/JCO.2008.21.2480. Epub 2009 Apr 6. No abstract available.

PMID:
19349537
3.

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.

Teft WA, Welch S, Lenehan J, Parfitt J, Choi YH, Winquist E, Kim RB.

Br J Cancer. 2015 Mar 3;112(5):857-65. doi: 10.1038/bjc.2015.5. Epub 2015 Jan 22.

4.

Usefulness of one-point plasma SN-38G/SN-38 concentration ratios as a substitute for UGT1A1 genetic information after irinotecan administration.

Hirose K, Yamashita K, Takada H, Kaneda N, Fukami K, Maruo E, Kitamura M, Hasegawa J, Maeda Y.

Int J Clin Oncol. 2014 Apr;19(2):397-402. doi: 10.1007/s10147-013-0558-1. Epub 2013 Apr 19.

PMID:
23605141
5.

ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.

Rhodes KE, Zhang W, Yang D, Press OA, Gordon M, Vallböhmer D, Schultheis AM, Lurje G, Ladner RD, Fazzone W, Iqbal S, Lenz HJ.

Drug Metab Lett. 2007 Jan;1(1):23-30.

PMID:
19356014
6.

UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients.

Onoue M, Terada T, Kobayashi M, Katsura T, Matsumoto S, Yanagihara K, Nishimura T, Kanai M, Teramukai S, Shimizu A, Fukushima M, Inui K.

Int J Clin Oncol. 2009 Apr;14(2):136-42. doi: 10.1007/s10147-008-0821-z. Epub 2009 Apr 24.

PMID:
19390945
7.

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.

Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS.

Cancer. 2007 Jul 1;110(1):138-47. Erratum in: Cancer. 2010 Aug 1;116(15):3749.

8.

Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.

Jada SR, Lim R, Wong CI, Shu X, Lee SC, Zhou Q, Goh BC, Chowbay B.

Cancer Sci. 2007 Sep;98(9):1461-7. Epub 2007 Jul 11.

9.

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.

Chen S, Villeneuve L, Jonker D, Couture F, Laverdière I, Cecchin E, Innocenti F, Toffoli G, Lévesque E, Guillemette C.

Pharmacogenet Genomics. 2015 Dec;25(12):573-83. doi: 10.1097/FPC.0000000000000168.

PMID:
26352872
10.

Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.

Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y.

Ther Drug Monit. 2002 Feb;24(1):111-6.

PMID:
11805731
11.

Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.

Sakaguchi S, Garcia-Bournissen F, Kim R, Schwarz UI, Nathan PC, Ito S.

Arch Dis Child. 2009 Dec;94(12):981-2. doi: 10.1136/adc.2009.163089. Epub 2009 Jul 15.

PMID:
19608554
12.

Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.

Takane H, Kawamoto K, Sasaki T, Moriki K, Moriki K, Kitano H, Higuchi S, Otsubo K, Ieiri I.

Cancer Chemother Pharmacol. 2009 May;63(6):1165-9. doi: 10.1007/s00280-008-0864-x. Epub 2008 Nov 8.

PMID:
18998132
13.

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ.

J Clin Oncol. 2004 Apr 15;22(8):1382-8. Epub 2004 Mar 8.

PMID:
15007088
14.

Pharmacogenetics of irinotecan disposition and toxicity: a review.

Fujita K, Sparreboom A.

Curr Clin Pharmacol. 2010 Aug;5(3):209-17. Review.

PMID:
20406168
15.

Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination.

Michael M, Thompson M, Hicks RJ, Mitchell PL, Ellis A, Milner AD, Di Iulio J, Scott AM, Gurtler V, Hoskins JM, Clarke SJ, Tebbut NC, Foo K, Jefford M, Zalcberg JR.

J Clin Oncol. 2006 Sep 10;24(26):4228-35. Epub 2006 Aug 8.

PMID:
16896007
16.

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.

Ramchandani RP, Wang Y, Booth BP, Ibrahim A, Johnson JR, Rahman A, Mehta M, Innocenti F, Ratain MJ, Gobburu JV.

J Clin Pharmacol. 2007 Jan;47(1):78-86.

PMID:
17192505
17.

Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer.

Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A.

J Clin Oncol. 1996 Oct;14(10):2688-95.

PMID:
8874328
18.

Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.

Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H.

Cancer Chemother Pharmacol. 2010 May;66(1):95-105. doi: 10.1007/s00280-009-1138-y. Epub 2009 Sep 22.

PMID:
19771428
19.

Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.

Crona DJ, Ramirez J, Qiao W, de Graan AJ, Ratain MJ, van Schaik RH, Mathijssen RH, Rosner GL, Innocenti F.

Pharmacogenomics J. 2016 Feb;16(1):54-9. doi: 10.1038/tpj.2015.23. Epub 2015 Apr 14.

20.

Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.

Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N.

Pharmacogenet Genomics. 2007 Jul;17(7):497-504.

PMID:
17558305

Supplemental Content

Support Center